Unidad de Investigación Clínica de Tumores Hematológicos H12O-CNIO

Inicio | Investigación e innovación | Programas Científicos | Programa de Investigación Clínica | Unidad de Investigación Clínica de Tumores Hematológicos H12O-CNIO

Joaquín Martínez
Joaquín Martínez Jefe de Unidad de Investigación Clínica
T +34 917328000 (Ext )
jmartinezl@ext.cnio.es

Investigadores

  • Santiago Barrio
  • Lucia Virginia Fernández
  • Miguel Gallardo
  • María Linares
  • Juan Manuel Rosa

Investigador Clínico I

  • Rosa María Ayala
  • María Calbacho
  • Gonzalo Carreño
  • María Pilar Carreras
  • María Teresa Cedena
  • Francisco Javier De La Serna
  • Ana Jiménez
  • María Inmaculada Rapado
  • Antonia Rodríguez
  • Ricardo Sánchez

Becarios Post-doctorales

  • Almudena García
  • Larissa Anita Haertle
  • Alejandra Leivas
  • Yanira Ruiz
  • Antonio Valeri
  • María Velasco

Becarios Pre-Doctorales

  • Pedro Aguilar
  • Noemí Álvarez
  • Eva Castellano
  • Laura Córdoba
  • Jessica Encinas
  • Roberto García
  • Marta Ibáñez
  • Elena Maroto
  • Michael Ochieng
  • María Alejandra Ortiz
  • Álvaro Otero
  • Alba Rodríguez
  • Laura Sánchez

Técnicos de Laboratorio

  • Raquel Ancos
  • Andrés Arroyo
  • Irene Bragado
  • Natalia Sofía Buenache
  • Sara Dorado
  • Adrián Fernández
  • Vanesa Garrido
  • Alicia Giménez
  • María Luz Morales
  • Laura Moreno
  • Miguel Ángel Navarro
  • Laura Rufián
  • Daniel Valdés

Haematology represents one of the most “hot topics” areas in cancer of the last 5 years, due to society’s growing interest in the immunology that drives one of the biggest discoveries of the 21st century, immunotherapy. In addition, haematology has been gaining traction because of the interest in applying peripheral blood analysis to determine the diagnosis and prognosis of multiple cancers and diseases, and in emerging promising cutting-edge technology such as liquid biopsy, a method currently used to measure minimal residual disease (MRD).

The Haematological Malignancies Clinical Research Unit focuses on 2 research areas: 1) novel immunotherapies against cancer and, more specifically, NK-CAR technology; and 2) the development and improvement of liquid biopsy protocols through next-generation-sequencing.

Moreover, our group investigates the molecular mechanisms of haematological malignancies and then uses the identified molecules and markers (e.g., PIEZO1, HNRNPK) to develop mouse models of the disease that could be exploited therapeutically.

Publicaciones

Subir